Slide 1: Corporate Presentation September 2023
Cfipca Ipca Laborate Corporate Presentation September 2023
Slide 2: About Us
About Us i Incorporation Total Income FY 2022-23 | Employees 70+ =—- %6,369.94cs | >16,000 | ee , “ years facilities labs —— US$794 nn | |
Slide 3: Our Values
Our Values i ( * Values « } Qualit? Safeti Integriti Digniti Responsibilit? Adhere to Ensure safety Comply with Value Facilitate good standards comes first ethics & standards people business practices
Slide 4: Five Years' Highlights (Standalone)
Five Years’ Highlights X Figures in Crores. Standalone ete >) 738.69 5,491.22 5,201.40 (8699.20) ($737.38) 4,432.12 (5625.65) 3,687.74 3,282.39 ($520.57) 2,983.09 ($409.17) dan (5400.58) €2,288:37 (SEED 1,956.90 ($323.03) es 2,643.42 22,717.19 2,508.13 Bait 2,143.75 (5365.26) (5336.80) ($329.52) 1,7
Slide 5: Five Years' Highlights (Consolidated)
Five Years’ Highlights Consolidated X 6,369.94 5,896.36 ($794.06) 5,482.83 ($791.78) ($737.03) 4,715.71 ($665.68) 3,830.86 ($540.77) 3,391.07 2,963.06 3,077.75 (5422.72) 2,327.88 ($398.31) ($413.29) 21,956.90 ($328.61) rae 22,519.77 &2,818.61 2,978.87 2,387.83 (5338.72) ($378.49) (5371.34) 21,873.96
Slide 6: Manufacturing Facilities: Formulations
Manufacturing Facilities Formulations
Slide 7: Manufacturing Facilities (Formulations)
Manufacturing Facilities (Formulations) Dehradun Kandla (2 facilities) (B-lactum) New Delhi Jorethang (2 facilities) Ratlam B capital BW Corporate Office B® Formulations @ rao | | SEZ - Pithampur Mumbai Mumbai (Biotech) (R&D) Athal Piparia Pithampur (Biotech) A. Open Tarapur
Slide 8: Manufacturing Facilities (Formulations)
Athal (Dadra & Nagar Haveli) Ratlam (Madhya Pradesh) Kandla (Gujarat) Silvassa (Dadra & Nagar Haveli) Dehradun (Uttarakhand) Indore (SEZ) (Madhya Pradesh) Sikkim Tarapur, Palghar (Maharashtra) Tablets & Capsules Tablets, Liquids, Dry Syrup, Injectables & Ointments Betalactum-Tablets, Capsules & Dry
Slide 9: Manufacturing Facilities: APIs
Manufacturing Facilities Active Pharmaceutical Ingredients (APIs)
Slide 10: Manufacturing Facilities (APIs)
Onyx Scientific (Sunderland, UK) Onyx Scientific (Sunderland, UK) * (R80) B@ capital f & Baroda ee BW Corporate Office ae @ aris B® rao @ KT] ets Pisgah Labs Pisgah Labs (North Carolina, USA) (North Carolina, USA) (R&D) Ankleshwar J Dewas Nandesari | Wardha Tarapur Manufacturing Facilities (APIs) 5
Slide 11: Manufacturing Facilities (APIs)
Manufacturing Facilities (APIs) | Location | Inspections / Approvals by Agencies of | @ Ratlam (Madhya Pradesh) Australia, Brazil, Canada, EDQM, EU, India, Japan, Korea, Mexico, Russia, USA, WHO @ Dewas (Madhya Pradesh) India © Ankleshwar(Gjart) =U, India Japan, Meco @ Nandesari (Gujarat) EU, India
Slide 12: Revenue Break-up
Revenue Break-up 2021-22 & 2022-23
Slide 13: Revenue Break-up
Revenue Break-up Standalone 2022-23 Total Total Revenue Exports Domestic 2022-23 2022-23 2022-23 2022-23 45% 38% 62% FF e e APIs Formulations | Export Domestic | APIs Formulations! APIs Formulations G Formulations @ APIs B Domestic HB Exports @ Formulations @ Apis B Formulations @B Apis
Slide 14: Revenue Break-up
Revenue Break-up Standalone 2022-23 2021-22 Crs | Domestic | Exports | Total | [ Domestic | Exports | Total Growth © Branded Formulations 2760.71 504.79 3265.50 2508.27 415.99 2924.26 q rene isiton/ : 1134.40 1134.40 : 1070.75 1070.75 © Total Formulations 2760.71 1639.19 4399.90 2508.27 1486.74 3995
Slide 15: Financials
Financials FY 2021-22 & FY 2022-23
Slide 16: Financials Standalone
Financials Standalone FY 2022-23 FY 2021-22 XCrs US$ Mn | [ XCrs US$ Mn | % Growth | @ Total Income 5925.81 B9 5491.22 8% e EBIDT 1054.05 131 1259.52 © EBIDT% 17.79% - 22.94% @ PBT# 750.49 94 1074.11 @ PBT% 12.66% - 19.56% © PAT* 505.70 63 860.37 © PAT% 8.53% - 15.67% # After forex loss of $31.01 Cr
Slide 17: Profitability
Financials Standalone Profitabilit [OO y 7 FY 2022-23 FY 2021-22 @ point @ pet WB PAT @ Point @ pot @ PAT
Slide 18: Business Characteristics
Business Characteristics Return on Capital Employed % (PBIT / Capital Employed) Return on Net Worth % (PAT / Net Worth) Fixed Asset Turnover Ratio (Total Income / Net Fixed Assets) Capital Employed Turnover Ratio (Total Income / Capital Employed) Asset Coverage Ratio (to term loan) (Net Fixed Assets
Slide 19: Financials Standalone Growth
Financials Standalone FY 2022-23 FY 2021-22 © Domestic Sales 9.3% 19.7% EE ee @ PBIDT -16.3% 17.4% © Net Profit 41.2% 23.7%
Slide 20: Q1 FY 2024 Standalone
Q1 FY 2024 Q1 FY 2023 Crs US$ Mn | [ XCrs | US$ Mn | % Growth | @ Total Income 1529.50 186 1496.24 193 2% @ EBIDT 284.28 35 269.27 35 @ EBIDT% 19.13% = 18.21% = P| @ PBT* 249.58 30 211.39 27 @ PBT% 16.79% 2 14.30% - | @ PAT# 166.58 20 140.07 18 @ PAT% 11.21% = 9.48% = P| a # After forex gain of €13.
Slide 21: Q2 FY 2024 Standalone
Standalone Q2 FY 2024 Q2 FY 2023 XCrs US$ Mn | [ Crs US$ Mn | % Growth | @ Total Income 1698.81 205 1530.16 192 11% e EBIDT 346.77 42 281.74 35 © EBIDT% 20.86% - 18.85% - @ PBT# 245.13 30 240.39 30 @ PBT% 14.74% - 16.08% 2 © PAT* 162.13 20 165.63 a © PAT% 9.75% - 11.08% # After forex gain of $1.50 C
Slide 22: H1 FY 2024 Standalone
H1 FY 2024 H1 FY 2023 © Total Income @ EBIDT @ EBIDT% @ PBT* @ PBT% @ PAT# @ PAT% Crs US$ Mn | [ Crs US$ Mn | % Growth | 3228.31 392 3026.40 386 7% 631.05 77 551.01 70 494.71 60 451.78 58 15.71% 2 15.20% 2 328.71 40 305.70 39 # After forex gain of $14.95 Crs as against forex loss of $25.91 Crs for p
Slide 23: Financials Consolidated
Financials Consolidated FY 2022-23 FY 2021-22 XCrs US$ Mn | [ Crs US$ Mn | % Growth | @ Total Income 6369.94 794 5896.36 8% e EBIDT 1083.77 135 1345.04 e@ EBIDT% 17.01% - 22.81% @ PBT* 745.29 93 1135.72 @ PBT% 11.70% - 19.26% @ PAT* 471.32 59 884.08 @ PAT% 7.40% - 14.99% # After forex loss of 31.38
Slide 24: Business Characteristics
Business Characteristics Return on Capital Employed % (PBIT / Capital Employed) Return on Net Worth % (PAT / Net Worth) Fixed Asset Turnover Ratio (Total Income / Net Fixed Assets) Capital Employed Turnover Ratio (Total Income / Capital Employed) Asset Coverage Ratio (to term loan) (Net Fixed Assets
Slide 25: Financials Consolidated Growth
Financials Consolidated FY 2022-23 FY 2021-22 © Domestic Sales 9.5% 22.7% EE Ee @ PBIDT -19.4% 14.1% @ Net Profit 46.7% -22.4%
Slide 26: Q1 FY 2024 Consolidated
Q1FY 2024 Q1 FY 2023 Crs UssMn | ts USS Mn %Growth | @ Total Income 1630.06 198 1607.85 © EBIDT 294,33 36 283.46 © EBIDT% 18.57% : 17.88% © PBT# 251.82 31 222.69 © PBT% 15.89% c 14.04% © PAT# 162.82 20 143.06 © PAT% 10.35% : 9.02% # After forex gain of €13.49 Crs as against forex loss of $14.23 Crs
Slide 27: Q2 FY 2024 Consolidated
Q2 FY 2024 Q2 FY 2023 XCrs US$ Mn | [ Crs US$ Mn | % Growth | @ Total Income 2072.51 251 1637.18 205 27% e EBIDT 358.77 43 272.23 34 e@ EBIDT% 17.64% - 17.00% = @ PBT* 225.36 27 223.82 28 @ PBT% 11.08% - 13.98% 2 @ PAT* 145.06 18 143.90 18 @ PAT% 6.71% - 9.11% # After forex gain of $1.79 Crsas again
Slide 28: H1 FY 2024 Consolidated
H1 FY 2024 H1 FY 2023 %Crs US$ Mn | [ Crs US$ Mn | % Growth | @ Total Income 3702.57 449 3245.03 414 14% @ EBIDT 653.10 79 555.69 71 @ EBIDT% 18.05% = 17.44% = @ PBT* 477.18 58 446.51 57 @ PBT% 13.18% 2 14.01% 2 @ PAT# 307.88 37 286.96 37 # After forex gain of $15.28 Crs as against forex loss of $25
Slide 29: Contribution of Therapeutic Groups
© Cardiovasculars& Anti Diabetics e © Anti‘Malarals e 3% 5% © ‘Neuro Psychiatry e 3% 3% © Dermatology e % 5% © ‘Neutraceuticas es 1% 1% ee a) Financials Standalone Contribution of Therapeutic Groups a Wiles Segment — 2022-23 Domestic 2021-22 Export 2022-23 2021-22 © Cardiovasculars & Anti-Diabetics
Slide 30: Branded Formulations Domestic
Branded Formulations Domestic
Slide 31: Branded Formulations Domestic
Branded Formulations i Domestic , 21 Market leaders in All India Rank 1QVIA Therapy Focused Over 4000 Rheumatoid Arthritis 1 7th (MAT Sept’23) Marketing Divisions Wholesalers & Anti-malarials ® OD @ € 24 Depots & Field Strength 5 brands among 1 CaF agent (PSR / BA)-6233 top 300 brands (Zerodol-SP, Z
Slide 32: Branded Formulations Domestic Sales
Branded Formulations Domestic 2760.71 3000 2508.27 ($344Mn) ($337 Mn) 2500 1912.61 1981.67 2000 ($270 Mn) ($266 Mn) 1500 1000 500 —O- 102-2 0 1 2019-20 L 2019-20 2020-21 2021-22 2022-23 y ene Figures in Crores. Sales
Slide 33: Future Growth Drivers
Branded Formulations Domestic Future Growth Clinical research as a tool to launch innovative combination Drivers formulations / NDDS. ail —e Strong brand building with focused promotion. -—® In-licensing / out-licensing to build business in the promoted therapy. Portfolio optimisation, strategies to
Slide 34: International Business
International Business
Slide 35: International Business
International Business Registrations in 58 countries Q Recognised _A Field-force to promote brands © Star Trading Fail) in more than House 35 countries Products of the company 41% sales & Marketing officesin are now exported to over From exports By 12 countries 100 countries across the globe
Slide 36: International Business Sales
International Business 3000 22717.19 22643.42 ($365 Mn) ean ($330 Mn) 2500 €2143.75 ($303 Mn) 2000 1500 1000 500 —O- 2022-3 0 1 1 1 2019-20 L 2019-20 2020-21 2021-22 2022-23 y ene Figures in Crores. Sales
Slide 37: Continent-wise Exports 2022-23
International Business i Continent-wise Exports 2022-23 (%Crs) Continent Formulations APIs | Total | % Contribution | © Europe 486.11 273.53 759.64 29% © Africa 416.76 55.05 471.81 18% © Americas 163.17 297.79 460.96 17% © Asia 110.82 341.52 452.34 17% e ds 188.44 32.53 220.97 8% © Australasia 273.8
Slide 38: International Formulations
International Formulations
Slide 39: International Formulations Sales
International Formulations XX 1597.19 ($215 Mn) 1486.74 ($200 Mn) %1221.55. ~\ 1639.19 ($204 Mn) ($172 Mn) —O- 102-2 2019-20 2020-21 2021-22 T 1 2019-20 ms OB Figures in Crores. Sales
Slide 40: International Branded Formulations
International Branded Formulations
Slide 41: International Branded Formulations Sales
International Branded Formulations ( > HEU 504.79 510 ($63 Nn) 490 470 450 430 415,99 no %403.42 ($56 Mn) 2381.53 ($54Mn) 390 ($54 Mn) 370 350 —O- 2022-3 330 T 1 1 1 2019-20 L 2019-20 2020-21 2021-22 2022-23 O- mon Figures in Crores. Sales
Slide 42: Future Growth Drivers
Future Growth Drivers al International Branded Formulations Thrust on brand building in Pain, CVS, CNS, Anti-infective and Anti-malarial segments. Geographical expansion in covered countries through additional field force. Expansion in business lines - Institutions and Distributors. Introduction of
Slide 43: Generics / Institution / Tender
International Generics / Institution / Tender
Slide 44: Generics / Institution / Tender
International Generics / Institution / Tender a \ Count Products Products Under 1400 er ountry Registered Registration \ =1134.40 m 160 M United Kingdom / 1200 ($ n) 1070.75 ($141 Mn) Euroa 9 4] 7 ($144 Mn) 1000 840.02 Australia / B 3 ($119 Mn) New Zealand 800 South Africa 53 10 600 United States /
Slide 45: International Generics Future Growth Drivers
International Generics Future Growth Drivers Dossiers developed by company approved in UK are being taken for registration in other EU countries. Al Formulations registered to be backed by own API. Sale of generic dossiers with or without supply agreements. Contract manufacturing arrangements. Futur
Slide 46: International APIs
International Active Pharmaceutical Ingredients (APIs)
Slide 47: International APIs Sales
International APls ( 1120.00 >) 1200 (S151 Mn) a 021.39 1004.23 137 Mn ($125 Mn) 922.20 1000 (6130 Mn) 800 600 400 200 —O- 2022-3 0 1 1 1 2019-20 L 2019-20 2020-21 2021-22 2022-23 y ene Figures in Crores. Sales
Slide 48: APIs - Drug Master Files
International APIs - Drug Master Files Any PME | Name of the API sepa | Canada | wHo | /3P@ pustralia | EQDM 1 1 Alendronate Sodium g : - Vv) - @ 2 2 Allopurinol @ 7) = = cy 7) 3 3 Amlodipine Besylate g : - - - v) 4 Amlodipine Besylate (AK4 Process) - - = 2 - () 4 5 Amodiaquine HCI = ° () - - - 5 6
Slide 49: APIs - Drug Master Files
API | DMF Sr. No. | Sr. No. 11 12 12 13 13 14 14 15 16 15 7 16 18 19 7 20 18 21 19 22 Name of the API Benzarone Benzbromarone Bisoprolol Fumarate Carvedilol Cetrizine Hydrochloride (CZ Process) Cetrizine Hydrochloride (CZ5 / CZ6 Process) Chloroquine Phosphate Chlorthalidone (CT3 / CT7 Process) Chlor
Slide 50: APIs - Drug Master Files
International APIs - Drug Master Files Any PME | Name of the API sepa | Canada | wo | Japan | australia | EQDM 23 Etodolac (ED6 Process) i] 2 - - - - 20 24 Etodolac (ED7 Process) @ = - - @ n 25 Famotidine = = : ) - uv) 26 Famotidine (FM3 Process) - - - - - i) 22 27 Fenofibrate - - - - - @ 23 28 Fluc
Slide 51: APIs - Drug Master Files
International APIs - Drug Master Files Any PME | Name of the API sepa | Canada | wo | Japan | australia | EQDM 33 Hydrochlorothiazide (Process I) @ () - ) CEP @ 27 34 Hydrochlorothiazide (Process II) @ - - - = @ 35 Hydrochlorothiazide (Process III) - - = 2 - @ 28 36 Hydroxychloroquine Sulphate @ @ -
Slide 52: APIs - Drug Master Files
API | DMF Sr. No. | Sr. No. 34 44 35 45 36 46 47 37 48 49 38 50 39 51 40 52 53 4] 54 Name of the API Lumefantrine Meloxicam Mesalamine (MZ4 Process) Mesalazine Mesalazine (MZ4B Process) Metformin HCL (ML Process) Metformin HCL (ML2 Process) Methylphenidate HCI Metoclopramide Base Metoclopramide HCI
Slide 53: APIs - Drug Master Files
API | DMF Sr. No.| Sr. No. 42 55 43 6 57 44 58 45 59 46 60 47 61 48 62 49 63 50 64 51 65 Name of the API Metoprolol Succinate Metoprolol Tartrate Metoprolol Tartrate (03 / 05 Process) Midodrine Hydrochloride Nabumetone Nifedipine Olanzapine Ondansetron Base Ondansetron Hydrochloride Paroxetine HCI P
Slide 54: APIs - Drug Master Files
API | DMF Sr. No.| Sr. No. 52 66 53 67 54 68 55 69 56 70 57 71 58 72 59 73 60 74 61 75 62 76 Name of the API Primaquine Phosphate Probenecid Proguanil Hydrochloride Promethazine Hydrochloride Propranolol HCI Pyrantel Embonate Pyrantel Pamoate Pyrimethamine Quetiapine Fumarate Ractopamine HCI Risedro
Slide 55: APIs - Drug Master Files
International APIs - Drug Master Files API-DMFs Filed as on Sept'23 (Based on DMFs Sr. No.) API | DMF Canada- Japan- A Sr.No.|Sr.No.| Name of the API US-FDA HPFB WHO irl Australia EQDM | 78 Telmisartan - 2 - - - ea bd 79 Telmisartan (WT3A Process) a 81 Tramadol Hydrochloride 66 82 Tramadol Hydrochlo
Slide 56: APIs - Drug Master Files
International APIs - Drug Master Files API-DMFs Filed as on Sept'23 (Based on DMFs Sr. No.) API | DMF r Canada- Japan- ; E No. on Sr. N al Name of the API | US-FDA | HPFB | WHO PMDA | Australia | EQDM 88 Valsartan (VA2 Process) ° ) - - - . 69 89 Valsartan (VA6 Process) @ - - - - vv) 70 90 Venlafexin
Slide 57: International APIs Future Growth Drivers
International APIs -—® Consolidate API business of Sartans across the globe. Future Growth Drivers -—e Long term strategic tie-ups with major South American / European formulators. Leverage the customer base of more than 1000 customers spread across 90 A countries is well laid down platform to intro
Slide 58: Research & Development
Research & Development APIs & Formulations
Slide 59: R&D Spending
Research & Development APls & Formulations ( 2156.49 160 146.46 2.71% 4.00% | Year | Crs % to Sales 2.63% 140 =126.67 3.50% 2018-19 89.35 2.50% 2.49% 120 $89.35 €101.04 3.00% 2019-20 101.04 235% 2.50% 2.35% 0 we ae 2020-21 126.67 2.49% 80 2.00% 2021-22 141.46 2.63% 60 1.50% ms 1.00% 2022-23 156.49 2
Slide 60: Research & Development: APIs & Formulations
oul Research & Development APls & Formulations Current scientist manpower of 550+. Research focus on developing APIs with non-infringing process and development of finished dosage forms. Development of NDDS for domestic and international market. 248 patent applications filed. Biotech / fermentation
Slide 61: Inception of Advanced Biotech Lab
Inception of Advanced Biotech Lab Biosimilar R&D -—® Established “state-of-the-art” R&D in 2015 for Mammalian based mAbs Capable of in-house development from “Clone to Commercialization” Single-use cGMP Bio-manufacturing Facility (DS-+DP) is being established and to be ready by July 2024 —e Scientif
Slide 62: Strong Biosimilar Pipelines
Strong Biosimilar Pipelines i Molecules: Anti-cancer and Anti-inflammatory mAbs Stage of Development * 6 monoclonal antibodies (mAbs) in various | Molecules ‘Development| Pre-clinical | cinical Trials MAA/ Launch) stages of the development UK/IN/EU Target markets India, UK, EU, ROW followed by USA (
Slide 63: lout prior approval of lpca Laboratories Limit
lout prior approval of lpca Laboratories Limit Oh aurcurtentd isiniess. expectations: Ouractual tesults may differ — jeviewers of this presentation. may use their owi judgment and calculation: nformation given herein: e any of theinformation given in this presentation.